Form 4: Theravance Biopharma Director Grant Acquires Shares and Options
SEC Form 4 Filing
Director Jeremy T Grant reports acquisition of Theravance Biopharma shares and options in a recent SEC filing.
Summary
- On May 8, 2024, Jeremy T Grant, a director of Theravance Biopharma, Inc. [TBPH], reported transactions involving the company's securities.
- Grant acquired 10,537 ordinary shares at $0 and disposed of 22,305 shares.
- Following these transactions, Grant beneficially owns 22,305 ordinary shares.
- Grant also acquired 23,576 share options with an exercise price of $9.49, expiring on May 7, 2034.
- These options vest in monthly installments and fully vest on the date of the next annual meeting of the company's shareholders, provided continuous service.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a standard disclosure of insider transactions.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 05/08/2024 | Date of the reported transactions: acquisition and disposal of ordinary shares and acquisition of share options. |
| 05/07/2034 | Expiration date of the acquired share options. |
| 05/10/2024 | Date of signature by Attorney-in-Fact, Brett A. Grimaud. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.